FGFR2 and gastric cancer: On the other hand, along with another group, we previously reported that FGFR2 amplification confers hypersensitivity to FGFR inhibitor in gastric cancer cell lines both in vitro and in vivo (Nakamura et al, 2006; Takeda et al, 2007), strongly suggesting that FGFR2 amplification may be a promising molecular target for the treatment of FGFR2-amplified gastric cancer.